Acta Scientific Cancer Biology (ASCB) (ISSN: 2582-4473)

Research Article Volume 4 Issue 12

Challenges and Management in Gynaecological Cancers in Covid 19 Crises: An Institutional Experience

Sumit Kumar3, Vishal Kaundal2, Shilpa Sood6, Vandana Singh Kushwaha5, Shalini Verma1*, Muninder Negi1 and Nitin Gupta4

1Radiation Oncology Department, Dr RPGMC Tanda, India
2Surgery Department, Dr RPGMC Tanda, India
3Radiation Department, AIIMS, NEW Delhi, India
4Nuclear Medicine Department, Dr RPGMC Tanda, India
5Radiation Oncology Vydehi Institute of Medical Sciences and Research, India
6Gynaecology, Lady Harding, India

*Corresponding Author: Shalini Verma, Radiation Oncology Department, Dr RPGMC Tanda, India.

Received: October 23, 2020; Published: November 18, 2020



Objective: To illustrate our institutional experience about the challenges we faced and steps taken in the management of the patients with gynaecological malignancies during Covid-19 crises at Dr. R.P.G.MC Tanda.

Methods: The recommendations and guidelines framed by the World Health Organization and other international authorities were followed.

Results: With our multidisciplinary approach and intensive efforts we tried to provide all the feasible services to the ones requiring urgent and active treatment while at the same time protecting the ones (from Covid-19 infection ) not in immediate need of treatment by postponing their visits and treatment.

Conclusion: Covid 19 pandemic has resulted in unprecedented global healthcare crises. Our institution has illustrated the challenges faced in managing patients with gynaecological cancers. Due to the fear of increased risk of Covid-19 infection in the cancer patients which would result in devastating complications and very poor outcome, the preventive steps taken resulted in appreciable upstaging and progression of disease on imaging and blood investigations.

Keywords: COVID-19; Pandemic; Gynaecological Cancer Care



  1. Docea AO., et al. “A new threat from from an old enemy: Re-emergence of coronavirus (Review)”. International Journal of Molecular Medicine 45 (2020): 1631-1643.
  2. Liang W., et al. “Cancer patients in SRAS-CoV-2 infection: A Nationwide analysis in China”. Lancet Oncology3 (2020): 335-337.
  3. Zhang J., et al. “Management strategies for three patients with gynaecological malignancies during the outbreak of COVID19”. Zhonghua fu Chan ke za zhi4 (2020): 221-226.
  4. Shen SC., et al. “Factors involved in the delay of treatment initiation for cervical cancer patients: A nationwide population-based study”. Medicine33 (2016): e4568.
  5. Allam JA., et al. “The effect of the overall treatment time of fractionated-irradiation on the tumour-control probability of a human sofe-tissue sarcoma xenograft in nude-nice”. International Journal of Radiation Oncology 32 (1995): 105-111.
  6. Fyles A., et al. “The effect of treatment duration in the local control of cervix cancer”. Radiotherapy Oncology 25 (1992): 273-279.
  7. Petereit DG., et al. “The adverse effect of treatment prolongation in cervical cancer”. International Journal of Radiation Oncology • Biology • Physics 32 (1995): 1301-1307.
  8. Tandrup K., et al. “Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachtherapy of locally advanced cervical cancer”. Radiotherapy Oncology 120 (2016): 441-446.
  9. Sedlis A., et al. “A randomized trial of pelvic radiation therapy versus no further therapy in selected pateints with stage IB carcinoma of the cervix after radical hystrectomy and pelvic lymphadenectome: A gynaecologic Oncology Group Study”. Gynecology and Oncology 73 (1999): 177-183.
  10. Peters WA., et al. “Concurrent Chemotherapy and pelvic radiation in high risk early stage cancer of the cervix”. Journal of Clinical Oncology 18 (2000): 1606-13.
  11. Shalowitz DI., et al. “Survival implications of time of endometrial cancers”. American Journal of Obstetrics and Gynecology 3 (2017): 268e1-268e18.
  12. Ahmad NR., et al. “Postoperative radiation therapy for surgically staged endometrial cancer- Impact of time (overall tretament time and surgery to radiation interval on outcome”. International Journal of Radiation Oncology 33 (1995): 837-842.
  13. Fabrini MG., et al. “Relationship between interval from surger to radiotherapy and local recurrence rate in patients with endometroid type endometrila cancer: A retrospective mono-institutional Italian Study”. Anticancer Research 32 (2012): 169-173.
  14. Liu Y., et al. “Relationship between initiation time of adjuvant chemotherapy and survival in ovarian cancer patients: A dose-response meta-analysis of cohort studies”. Scientific Report1 (2017): 1-8.
  15. Ramirez PT., et al. “COVID-19 pandemic: options for management of gynecologic cancers”. International Journal of Gynecological Cancer 5 (2020): 561-563.
  16. Udeta M., et al. “Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal”. Journal of the National Comprehensive Cancer Network 20 (2020): 1-4.
  17. Huang C., et al. “Clinical features of patiens infected with 2019 novel coronavirus in Wuhan, China”. Lancet 10223 (2020): 497-506.
  18. Zhou FD., et al. “Clinical course and risk factors for mortality of adults in patients with COVD-19 in Wuha, china: A retrospective study”. Lancet 10229 (2020): 1054-1062.
  19. Sapkota S., et al. “Ovarian cancer practice survey from the South Asian Association for Regional Cooperation (SAARC) Nations”. Cancer Research, Statistics, and Treatment 2 (2019): 158-162.
  20. Kaur S and Singh R. “Patterns of care for ovarian cancer”. Cancer Research, Statistics, and Treatment 2 (2019): 217-220.
  21. Akladios C., et al. “Recommendations for surgical management of gynecological cancers during the COVID-19 pandemic”. Journal of Gynecology Obstetrics and Human Reproduction 6 (2020): 101729.


Citation: Shalini Verma., et al. “Challenges and Management in Gynaecological Cancers in Covid 19 Crises: An Institutional Experience". Acta Scientific Medical Sciences 4.12 (2020): 03-09.